* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Changing the way the world looks at TB
Survey
Document related concepts
Germ theory of disease wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
Vaccination wikipedia , lookup
Urinary tract infection wikipedia , lookup
Globalization and disease wikipedia , lookup
Sociality and disease transmission wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
Sarcocystis wikipedia , lookup
Hepatitis C wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Neonatal infection wikipedia , lookup
Tuberculosis wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
Coccidioidomycosis wikipedia , lookup
Transcript
Changing the way the world looks at TB QuantiFERON®-TB Gold www.QuantiFERON.com Identifying TB Infection is essential Tuberculosis (TB) remains a significant threat to humanity. At least one billion people are thought to be infected. A person who is infected with Mycobacterium tuberculosis, but who shows no symptoms and is not sick with the disease, is regarded as having latent TB infection (LTBI). Incidence of global TB Importance of treating TB infection Diagnose /treat Latent TB only Diagnose /treat Active TB only Although not everyone who becomes infected with TB bacteria develops active TB disease, individuals with latent TB and a compromised immune system are more likely to progress to active TB. Certain communities remain at higher risk of TB infection (CDC. Questions and Answers about TB), including: healthcare workers the elderly Diagnose /treat Latent and Active TB Increasing focus area over time to 2050 Theoretical graph of how treating latent and active TB together can overcome global TB burden. Model supported by data from Dye & Williams (J R Soc Interface 2008). immigrants homeless inmates military personnel people taking certain medications (ie. TNF-blocker medications) people with a weakened immune system public health officials working with TB control. Approximately one in every 10 people with TB infection will progress to active TB (CDC Fact Sheet: The Difference Between Latent TB Infection and Active TB Disease). The key to controlling TB is accurately and efficiently identifying the one in 10. Global organizations are beginning to acknowledge that to fight TB effectively, identifying and treating latent TB infection—as well as active TB disease—are vital. “…eliminating TB by the mid-century is most likely to be achieved if current treatment programmes can be coupled with new approaches to reduce the vast reservoir of latent human [TB] infection.” Dye & Williams (J R Soc Interface 2008). 2 Changing the way the world looks at TB It’s time for a change (per cumulative year) 500 400 300 200 100 20 10 08 20 06 20 04 20 02 20 20 00 0 98 A new paradigm in diagnosing TB infection is now available: Interferon-gamma release assays (IGRAs). IGRAs are blood tests that detect TB infection with significantly higher specificity and sensitivity than the TST. QFT peer-reviewed Clinical References 19 Previously, the only tool available for identifying TB infection was the Tuberculin Skin Test (TST),or Mantoux. The TST measures immune responses to tuberculin PPD, which is made up of a multitude of bacterial proteins. Most of these proteins are present in the TB vaccine, Bacille CalmetteGuérin (BCG), and shared with many environmental mycobacteria. The TST has several limitations including subjective results and frequent false positives often due to cross-reactivity with BCG vaccination or responses to environmental mycobacteria. The most clinically tested and proven IGRA is the QuantiFERON®-TB Gold In-Tube test (QFT®). QFT is a highlyspecific, controlled blood test for diagnosis of infection with the bacteria responsible for TB. QFT provides results with a high degree of accuracy. With over 450 published, peerreviewed clinical references, QFT is the most researched IGRA. Its clinical value is now well-proven. Unlike the TST: QFT is unaffected by previous BCG vaccination and most other environmental mycobacteria. QFT requires only one patient visit. QFT does not boost subsequent test results. QFT is a controlled laboratory test. QFT provides an objective, reproducible result that is unaffected by subjective interpretation. QFT results can be available within 24 hours. Changing the way the world looks at TB 3 QFT: the modern replacement for the TST When evaluating the impact of a test on TB screening programs, sensitivity and specificity are familiar parameters. How they interact with prevalence to influence negative and positive predictive values (NPV, PPV) and overall test accuracy is important to understanding the clinical significance of a test. The relationship between sensitivity, specificity, NPV, PPV, and accuracy is exemplified in the diagram below. By applying QFT and TST sensitivity and specificity estimates (Diel et al, Pai et al), QFT delivers a significant improvement over the TST in terms of both NPV and PPV at prevalence rates between 0 % and 50+ %. For example, when TB prevalence is 20%—a realistic rate in contact investigations—QFT provides close to 50% improvement in accuracy compared with the TST. QFT’s increased accuracy has significant and tangible benefits for TB control programs—better outcomes for patients, more confidence in correctly identifying TB infection, and significant cost savings through fewer false-positive results. Studies show that switching to QFT provides significant program cost advantages— over $64,000 saved per 1000 people tested, even if investigation of false-positives includes only chest X-rays and physician exams. Significant savings through fewer QFT false-positives 200 people 1,000 people 800 people True Negatives False Positives 794 True negatives per 1000 tests False positives per 1000 tests 176 624 6 QFT TST (1– 0.992)x800 (1– 0.78)x800 QFT (0.992)x800 $64,000 savings with QFT TST (0.78)x800 TST QFT Sensitivity (Se)*: 71.5% Sensitivity*: 84.5% Specificity (Sp): 78.0% Specificity*: 99.2% TST QFT Cost Difference (per 1000 tested) Chest X-ray 176 x $300 = $52,800 6 x $300 = $1,800 $51,000 Physician exam 176 x $ 80 = $14,080 6 x $ 80 = $480 $13,600 Total savings with QFT vs TST based on false-positive results: $64,600 *Data from Diel et al, Chest, 2010; `Calculated for a 50 % BCG vaccinated population, data from Pai et al, Annals Int Med, 2008. 4 Changing the way the world looks at TB Highly-specific in vitro blood test Quantification of interferon-gamma levels stimulated by TB-specific antigens, ESAT-6, CFP-10, TB7.7(p4) Non-specific in vivo skin test Measurement of induration caused by a non-specific response to tuberculin PPD Presentation of mycobacterial antigens Antigen Presenting Cell IFN-γ Effector Cell QFT contains TB mycobacterial proteins which are not found in the BCG vaccine. Because of this highly-specific composition, QFT overcomes virtually all of the shortcomings of the TST, with the added benefit of providing a laboratory-based, objective result. QFT is significantly more precise than TST in identifying people who will progress to active TB disease. QFT is significantly more sensitive, nearly halving the number of infected people missed by the TST. QFT is >99% specific, virtually eliminating false-positive readings (false positives by TST range from 3% to 65% of all persons tested, dependent upon the population). (Diel, et al. Am J Respir Crit Care Med, 2011; Diel, et al. Chest, 2010; Diel, et al. Am J Respir Crit Care Med, 2008; Pai, et al. Annals Int Med, 2008; Mori, et al. Am J Respir Crit Care Med, 2004) Changing the way the world looks at TB 5 IGRAs: Endorsed around the world Many countries around the world recognize IGRA technology for detecting TB infection. A considerable diversity of strategies exists: some countries have multiple guidelines regarding IGRAs, some have “official” government mandates while other institutions such as universities, hospitals, and medical professional societies provide policy and recommendations for TB infection testing. IGRAs preferred Other test preferred The CDC guidelines establish a new benchmark, recommending IGRAs as the preferred TB testing method for many patients, including BCG vaccinated and those unlikely to return for TST reading. “Updated guidelines for using Interferon-Gamma Release Assays to detect Mycobacterium tuberculosis infection—United States, 2010.” by CDC, MMWR. QFT / IGRA Guidelines and Recommendations Australia ASID 2009. NTAC 2007. Norway Folkehelseinstituttet 2010, 2009, 2007. Bulgaria 2011 Poland Kucharz et al. 2008. Canada CTC 2008, 2007. Portugal DGS 2011, 2010. Czech Republic CTS 2006. Romania NHIH 2010. Denmark DLHA 2010. Saudi Arabia Al Jahdali et al. 2010. EU ECDC 2011. EuroTB 2007. South Korea KCDC 2009. France HAS 2006. Spain SEPAR 2008. Germany DZK 2011, 2009, 2007. Switzerland SUVA 2010, 2007. Beglinger et al. 2007. Italy SIGE 2011. AIPO 2009. UK NICE 2011, 2006. HPA 2008. Japan Kekkaku 2010, 2008. JST 2006. USA CDC 2010, 2005, 2003. CDC Global Migration & Quarantine 2009, 2007. CDC/NIH/ISDA 2009. AAP 2009. ATS/CDC/IDSA 2009. US Armed Forces 2009. Netherlands KNCV 2007. New Zealand MOH 2010. Contact your local Cellestis representative for full reference listings. 6 Changing the way the world looks at TB QFT Procedure: Simple, reliable, reproducible QFT Procedure Blood collection Nil TB Antigen Mitogen Collect 1 ml of of Blood into Collect 1 ml Blood intoNil, Nil, Antigen, Antigen,and andMitogen Mitogentubes tubes Shake tubes tubes 10 10 times at room temperature. Shake temperature. Tubes can either incubated thentransported transported Tubes can either bebe incubated then to lab or sent directly to lab for incubation. to lab or sent for incubation. Shake 10x Manual Automated Centrifuge tubes separate plasma. Centrifuge tubes to to separate plasma. Complete Completethe theELISA ELISAand andobtain obtain absorbance values values absorbance Results Calculate results using QFT software Calculate results using QFT software These images are for illustrative purposes only. For full instructions, please refer to the QFT Package Insert on www.QuantiFERON.com. Changing the way the world looks at TB 7 QFT has been CE marked. QFT is approved by the US FDA QFT is approved by FDA as an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. It uses a peptide cocktail simulating ESAT-6, CFP-10 and TB7.7(p4) proteins to stimulate cells in heparinized whole blood. Detection of IFN-γ by ELISA is used to identify in vitro responses to these peptide antigens that are associated with M. tuberculosis infection. FDA approval notes that QFT is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography and other medical and diagnostic evaluations. QFT Package Inserts, available in up to 25 different languages, can be found at www.cellestis.com. Cellestis, a QIAGEN Company World Headquarters Cellestis Limited Email: [email protected] Tel: +61 3 8527 3500 Europe/Middle East /Africa Cellestis GmbH Email: [email protected] Tel: +49 6151 428 590 Japan/Korea QIAGEN KK Email: [email protected] Tel: +81 3 6890 7300 Australia/New Zealand Cellestis International Email: [email protected] Tel: +61 3 8527 3500 Asia/Pacific QIAGEN Singapore PTE Ltd Email: [email protected] Tel: +65 6854 8100 North America/South America Cellestis Inc. Email: [email protected] Tel: +1 661775 7480 (outside USA) Toll free: 800 519 4627 (USA only) QM05995192D www.QuantiFERON.com